Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CMO Sells $332,599.23 in Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CMO Robert Iannone sold 2,403 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $138.41, for a total value of $332,599.23. Following the completion of the transaction, the chief marketing officer now directly owns 79,621 shares in the company, valued at approximately $11,020,342.61. This represents a 2.93 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Robert Iannone also recently made the following trade(s):

• On Friday, March 7th, Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $138.60, for a total value of $981,288.00.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $136.05 on Friday. The firm has a market capitalization of $8.26 billion, a P/E ratio of 19.16, a P/E/G ratio of 1.04 and a beta of 0.44. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock’s 50-day simple moving average is $129.17 and its two-hundred day simple moving average is $120.60. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06.

Analysts Set New Price Targets

Several analysts have issued reports on JAZZ shares. UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the company from $145.00 to $179.00 in a research note on Friday, March 7th. Barclays restated an “overweight” rating and issued a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Cantor Fitzgerald lowered Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and boosted their target price for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. Truist Financial boosted their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. Finally, HC Wainwright boosted their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a research note on Monday. One research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Buy” and an average price target of $190.53.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. LSV Asset Management increased its stake in Jazz Pharmaceuticals by 1.5% in the 4th quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company’s stock worth $311,699,000 after acquiring an additional 37,108 shares during the last quarter. Pacer Advisors Inc. increased its stake in Jazz Pharmaceuticals by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock worth $272,713,000 after acquiring an additional 115,102 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock worth $250,619,000 after acquiring an additional 320,724 shares during the last quarter. Capital World Investors increased its stake in Jazz Pharmaceuticals by 5.7% in the 4th quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company’s stock worth $236,860,000 after acquiring an additional 104,195 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its stake in Jazz Pharmaceuticals by 20.9% in the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock worth $225,076,000 after acquiring an additional 315,608 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.